Exploring Gender Differences in Cancer Treatments – Bioengineer.org

Report on Sexual Dimorphism in Cancer: Molecular Mechanisms and Precision Oncology Perspectives

Introduction

A recent groundbreaking study published in Biological Sex Differences by Wang et al. explores the critical role of sexual dimorphism in cancer biology and treatment. This research provides vital insights into how biological sex differences influence cancer progression and therapeutic effectiveness. Given that cancer remains a leading cause of death worldwide, understanding these differences aligns with the United Nations Sustainable Development Goals (SDGs), particularly SDG 3 (Good Health and Well-being) and SDG 5 (Gender Equality), by promoting personalized and equitable healthcare solutions.

Understanding Sexual Dimorphism in Cancer

Sexual dimorphism refers to the biological differences between males and females, including size, color, and physiological features. Applied to oncology, these differences reveal new perspectives on tumor biology and patient management.

• Biological sex influences cancer predisposition, immune response, and treatment efficacy.
• Men and women exhibit distinct tumor microenvironments, necessitating gender-specific treatment approaches.
• Hormonal and genetic factors contribute to differential cancer susceptibility, e.g., prostate cancer in men and breast cancer in women.

Molecular Mechanisms and Hormonal Influences

The study highlights key molecular mechanisms underpinning sexual dimorphism in cancer:

1. Hormonal modulation: Estrogen and testosterone significantly affect tumor growth and progression.
2. Estrogen: Enhances proliferation of breast cancer cells.
3. Testosterone: Implicated in prostate cancer progression.

These findings support the development of sex-tailored therapeutic agents, advancing precision oncology and contributing to SDG 3 by improving treatment outcomes.

Immune Response Differences

Gender-based immune response variations impact cancer prevalence and treatment efficacy:

• Female patients generally exhibit stronger immune responses, potentially offering better protection against tumors.
• These differences affect immunotherapy outcomes, underscoring the need for sex-specific treatment protocols.

Precision Oncology and Clinical Implications

The research advocates for the integration of sex as a critical variable in cancer research and clinical practice:

• Inclusion of sex-based data in clinical trials to avoid historical underrepresentation of female patients.
• Refinement of therapeutic strategies to enhance efficacy and reduce side effects.
• Development of novel, gender-specific biomarkers for improved diagnostics and prognostics.

This approach supports SDG 9 (Industry, Innovation, and Infrastructure) by fostering innovation in healthcare technologies and SDG 10 (Reduced Inequalities) by promoting equitable treatment.

Broader Social and Healthcare Equity Considerations

The study’s implications extend to social dimensions of healthcare:

• Recognition of gender-based disparities in healthcare access and treatment effectiveness.
• Advocacy for inclusive healthcare systems that address unique challenges posed by sexual dimorphism.
• Promotion of gender-responsive frameworks in clinical oncology practice.

These efforts align with SDG 5 (Gender Equality) and SDG 10 (Reduced Inequalities), emphasizing equitable health outcomes.

Conclusion and Future Directions

Wang et al.’s research serves as a call to action for the medical community to:

1. Rethink conventional cancer research methodologies to incorporate sex differences.
2. Encourage interdisciplinary collaborations for holistic patient care.
3. Advance personalized oncology treatments that leverage biological sex differences.

By embracing these strategies, the global healthcare community can enhance cancer treatment efficacy and patient survival rates, contributing significantly to the achievement of SDG 3 and fostering a more inclusive, innovative, and equitable healthcare landscape.

Research Details

• Subject: Examination of Sexual Dimorphism in Cancer
• Article Title: Sexual dimorphism in cancer: molecular mechanisms and precision oncology perspectives
• Authors: Wang, Z., Hu, H., Bao, Y. et al.
• Published In: Biological Sex Differences (2026)
• DOI: 10.1186/s13293-026-00843-7

Keywords and Tags

Sexual dimorphism, cancer, precision oncology, tumor biology, immune response, gender-specific treatment, hormonal influences, genetic factors, personalized therapy, breast cancer, prostate cancer, tumor microenvironments.

1. Sustainable Development Goals (SDGs) Addressed or Connected to the Issues Highlighted in the Article

1. SDG 3: Good Health and Well-being
   • The article focuses on cancer, a major global health issue, and discusses improving treatment effectiveness and patient outcomes through personalized medicine.
   • It emphasizes the need for precision oncology and gender-responsive healthcare approaches.
2. SDG 5: Gender Equality
   • The study highlights sexual dimorphism and gender differences in cancer biology and treatment responses.
   • It calls for addressing gender disparities in healthcare access and treatment effectiveness.
3. SDG 9: Industry, Innovation, and Infrastructure
   • The research advocates for innovation in cancer diagnostics and therapeutics, including development of gender-specific biomarkers and precision oncology techniques.
4. SDG 17: Partnerships for the Goals
   • The article encourages interdisciplinary collaborations and integration of sex-based data in clinical trials, promoting partnerships across research and healthcare sectors.

2. Specific Targets Under Those SDGs Identified Based on the Article’s Content

1. SDG 3: Good Health and Well-being
   • Target 3.4: By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment.
   • Target 3.8: Achieve universal health coverage, including access to quality essential health-care services and access to safe, effective, quality, and affordable essential medicines and vaccines for all.
   • Target 3.b: Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries.
2. SDG 5: Gender Equality
   • Target 5.1: End all forms of discrimination against all women and girls everywhere.
   • Target 5.b: Enhance the use of enabling technology, in particular information and communications technology, to promote the empowerment of women.
3. SDG 9: Industry, Innovation, and Infrastructure
   • Target 9.5: Enhance scientific research, upgrade the technological capabilities of industrial sectors, including health technology innovation.
4. SDG 17: Partnerships for the Goals
   • Target 17.6: Enhance North-South, South-South, and triangular regional and international cooperation on and access to science, technology, and innovation.
   • Target 17.8: Fully operationalize the technology bank and science, technology and innovation capacity-building mechanism for least developed countries.

3. Indicators Mentioned or Implied in the Article to Measure Progress Towards the Identified Targets

1. Indicators Related to SDG 3
   • Mortality rates from cancer and other non-communicable diseases (NCDs) disaggregated by sex.
   • Proportion of patients receiving personalized or precision oncology treatments.
   • Inclusion rates of female and male participants in clinical trials to assess gender-specific treatment efficacy.
   • Development and validation of gender-specific biomarkers for cancer diagnosis and prognosis.
2. Indicators Related to SDG 5
   • Measures of gender disparities in healthcare access and treatment outcomes.
   • Data on the representation of women in clinical research and healthcare decision-making.
3. Indicators Related to SDG 9
   • Number of new gender-specific diagnostic tools and therapeutic agents developed.
   • Investment levels in cancer research focusing on sexual dimorphism and precision medicine.
4. Indicators Related to SDG 17
   • Number and quality of interdisciplinary and international collaborations focused on sex differences in cancer research.
   • Availability and accessibility of sex-disaggregated data in cancer research databases.

4. Table: SDGs, Targets and Indicators

Source: bioengineer.org